GT Biopharma (GTBP) Financials: Revenue & Earnings

GTBP price $5.59 +0.01 +0.27%

Ticker
GTBP
Price
$5.59
Change
+0.01 +0.27%
Market cap ?
$7.06M
P/E ?
-0.05
Forward P/E ?
22.38
Dividend yield ?
0.00%
Beta ?
0.85
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
53
Value
59
Quality
51
Growth
50

Stocklytics score rationale: value 59, quality 51, growth 50.

Financials

2016201720182019202020212022202320242025
0000000000

GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific…

Fair value

GTBP fair value $9.68. Price $5.59. Price is 42% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Compare GTBP

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-13—-2.50——
2026-08-14-3.00-2.00——
2026-05-21-0.11-2.00——
2026-03-02-55.50-5.50——
2025-11-13-0.83-9.50——
2025-08-13-0.55-17.00——
2025-05-21-0.33-16.00——
2025-03-25-1.67-38.75——
2024-11-14-1.53-2.70——
2024-08-16-54.25-67.50——
2024-05-15-41.00-67.50——
2024-03-28-54.75-67.50——
2023-11-01-1.50-2.50——
2023-08-10-41.26-2.50——
2023-05-15-5.25-4.00——
2023-03-30-4.50-4.25——
2022-10-31-5.50-2.75——
2022-08-11-2.50-4.25——
2022-05-16-4.25-7.75——
2022-03-28-13.00-5.25——
2021-11-10-4.75-5.25——
2021-08-23-3.25-7.00——
2021-05-17-45.75-6.00——
2021-04-16-84.75-1.00——
2020-11-13-20.43———
2020-08-14-40.86———
2020-05-15-10.21———
2020-03-27-9.25———
2019-11-14-219.61———
2019-08-14-25.54———
2019-05-15-45.96———
2019-03-29-35.75———
2018-11-15-71.50———
2018-08-14-91.93———
2018-05-15-102.14———
2018-03-01-51.00———
2017-11-14-4,208.29———
2017-08-11-63,283.75———
2017-04-28-157,472.00———
2017-03-31-6,267.75———

Dividends

Yield 0.00%. Payout ratio —. Frequency —.

Safety score 24/100 · At risk. Payout ratio is not reported, so this part stays neutral. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2025-09-04Mun-Gavin David C.Buy31.25K$1.3341.56K
2025-09-04Breen Michael MartinBuy100.00K$1.33133.00K
2025-09-04URBAN ALAN LOUISBuy50.00K$1.3366.50K
2025-09-04CASAMENTO CHARLES JBuy62.50K$1.3383.12K
2025-09-04Kramer HilaryBuy31.25K$1.3341.56K
2025-06-10Mun-Gavin David C.Other0——
2025-05-08Ritter Andrew JOther0——
2025-05-07Kramer HilaryOther0——
2024-10-17URBAN ALAN LOUISBuy23.34K$2.1149.24K
2024-06-03URBAN ALAN LOUISOther0——
2023-08-11Breen Michael MartinBuy200.00K$0.2957.40K
2023-08-11Ohri ManuBuy200.00K$0.2957.40K
2023-08-11Ohri ManuBuy200.00K$0.2957.40K
2023-08-11Ohri ManuSell200.00K$0.2957.40K
2023-06-16CASAMENTO CHARLES JBuy500.00K$0.35175.00K
2023-05-01CASAMENTO CHARLES JOther0——
2023-04-11Breen Michael MartinBuy50.00K$0.5025.00K
2023-04-06Ohri ManuBuy50.00K$0.5025.00K
2023-01-27Breen Michael MartinBuy500.00K$0.84418.50K
2023-01-27SHROTRIYA RAJESH C MDBuy500.00K$0.84418.50K
2023-01-27Ohri ManuBuy500.00K$0.84418.50K
2023-01-27Wendel BruceBuy500.00K$0.84418.50K
2022-07-15Breen Michael MartinBuy50.00K——
2022-07-15SHROTRIYA RAJESH C MDBuy50.00K——
2022-07-15URBAN ALAN LOUISBuy50.00K$2.48124.00K
2022-07-15URBAN ALAN LOUISBuy50.00K——
2022-07-15Berk GregoryBuy50.00K$2.48124.00K
2022-07-15Berk GregoryBuy50.00K——
2022-07-15Ohri ManuBuy200.00K——
2022-07-15Ohri ManuSell100.00K——
2022-07-15Wendel BruceBuy50.00K——
2022-06-09URBAN ALAN LOUISOther0——
2022-02-14Ohri ManuOther0——
2021-12-31Choy GavinBuy227.50K$3.05693.88K
2021-11-28Choy GavinOther0——
2021-02-25Breen Michael MartinBuy9.86K$3.4033.52K
2021-02-25Breen Michael MartinBuy40.24K$3.40136.83K
2021-02-25Breen Michael MartinSell30.00K$3.40102.00K
2021-02-16Berk GregoryBuy278.06K——
2021-02-16Berk GregoryBuy50.00K$6.33316.50K
2021-02-16SHROTRIYA RAJESH C MDBuy50.00K$6.33316.50K
2021-02-16Breen Michael MartinBuy278.06K——
2021-02-16Breen Michael MartinBuy50.00K$6.33316.50K
2021-02-16Wendel BruceBuy347.57K——
2021-02-16Wendel BruceBuy50.00K$6.33316.50K
2021-01-13SHROTRIYA RAJESH C MDOther0——
2020-12-22Wendel BruceBuy441$8.733.85K
2020-12-22Wendel BruceBuy1.37K$8.8712.19K
2020-12-22Weldon Steven WSell47.98K$0.4019.19K
2020-12-21Weldon Steven WSell50.00K$0.3015.00K
2020-12-21Weldon Steven WSell50.00K$0.3316.50K
2020-12-21Weldon Steven WSell35.72K$0.3412.15K
2020-12-18Weldon Steven WSell50.00K$0.3015.00K
2020-12-17Weldon Steven WSell50.00K$0.3015.00K
2020-12-17Weldon Steven WSell50.00K$0.3115.50K
2020-12-16Weldon Steven WSell50.00K$0.3015.00K
2020-12-15Weldon Steven WSell50.00K$0.3015.00K
2020-12-15Weldon Steven WSell50.00K$0.3015.00K
2020-12-15Weldon Steven WSell50.00K$0.3216.00K
2020-12-14Weldon Steven WSell50.00K$0.2814.00K
2020-12-14Weldon Steven WSell50.00K$0.2914.50K
2020-12-14Weldon Steven WSell46.30K$0.2913.43K
2020-12-11Weldon Steven WSell50.00K$0.2512.50K
2020-12-11Weldon Steven WSell50.00K$0.2613.00K
2020-11-16Wendel BruceBuy3.27K$3.1410.26K
2020-11-11Berk GregoryOther0——
2020-11-11Wendel BruceOther0——
2020-06-23Breen Michael MartinSell0$3.400
2020-06-02Cataldo TonySell4.23M$0.004.23K
2020-05-13Weldon Steven WSell2.27M$0.002.27K
2019-08-14Cataldo TonyBuy7.00M——
2019-08-14Weldon Steven WBuy4.50M——
2019-02-06Cataldo TonySell800.00K$0.00800
2019-02-01Urbanski Raymond W.Sell176.98K$0.00177
2017-11-16Cross ShawnOther0——
2017-11-02Cataldo TonySell200.00K——
2017-11-02Cataldo TonySell100.00K——
2017-11-02Cataldo TonySell3.00M——
2017-09-01Cataldo TonyBuy5.13M——
2017-09-01Urbanski Raymond W.Sell0——
2017-09-01Clarence-Smith KathleenSell0——
2017-09-01Weldon Steven WBuy2.57M——
2017-09-01Silverman Mark JSell0——
2016-04-05BRISTOL INVESTMENT FUND LTDBuy250.00K——
2016-04-04BRISTOL INVESTMENT FUND LTDSell675.00K$303,750.00205.03B
2016-02-09BRISTOL INVESTMENT FUND LTDSell0——
2016-01-25Cataldo TonySell0——
2016-01-25Weldon Steven WSell0——
2016-01-13BRISTOL INVESTMENT FUND LTDSell0——
2016-01-13BRISTOL INVESTMENT FUND LTDSell3.91M$1.254.89M
2012-03-01Saloff DavidBuy26.33M$0.041.05M
2011-08-31Saloff DavidBuy538.71K$0.0528.82K
2011-06-30Saloff DavidSell777.78K$0.0970.00K
2011-06-27Eaton Kenneth HaynesSell250.00K$0.0922.50K
2011-05-20DUBE ANSHUMANBuy0$0.100
2010-12-27DUBE ANSHUMANSell360.10K$0.1347.21K
2010-12-27Theorem Group, LLCSell360.10K$0.1347.21K
2010-12-23DUBE ANSHUMANSell700.00K$0.0535.00K
2010-12-23DUBE ANSHUMANBuy700.00K$0.0535.00K
2010-12-23DUBE ANSHUMANSell339.90K$0.1344.19K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 58, holders +19 vs prior quarter. Ownership 5.42%.

HolderSharesChangeChange %Value
VANGUARD CAPITAL MANAGEMENT LLC376.40K-75.48K-16.70%184.44K
GEODE CAPITAL MANAGEMENT, LLC266.79K-27.67K-9.40%130.65K
VANGUARD FIDUCIARY TRUST CO225.94K00.00%110.71K
HRT FINANCIAL LP107.14K107.14KNew52.00K
EVERHART FINANCIAL GROUP, INC.100.00K100.00KNew48.97K
ARAX ADVISORY PARTNERS93.63K00.00%45.85K
OPAL WEALTH ADVISORS, LLC81.81K81.81KNew40.06K
NORTHERN TRUST CORP75.46K75.46KNew36.95K
ALONGSIDE, LLC64.00K64.00KNew31.34K
49 WEALTH MANAGEMENT, LLC64.00K64.00KNew31.34K
CETERA INVESTMENT ADVISERS55.94K55.94KNew27.39K
SEACREST WEALTH MANAGEMENT, LLC50.10K100+0.20%24.53K
KITCHING PARTNERS, LLC50.00K50.00KNew24.48K
PNC FINANCIAL SERVICES GROUP, INC.40.00K40.00KNew19.60K
OSAIC HOLDINGS, INC.38.50K17.50K+83.33%18.86K
LPL FINANCIAL LLC36.38K6.00K+19.74%17.82K
MORGAN STANLEY22.57K5.97K+35.99%11.05K
KEEL POINT, LLC20.77K00.00%10.17K
INTEGRATED WEALTH CONCEPTS LLC20.01K00.00%9.80K
PRIVATE WEALTH MANAGEMENT GROUP, LLC20.00K00.00%9.79K
CORIENT PRIVATE WEALTH LP20.00K20.00KNew9.79K
SAGESPRING WEALTH PARTNERS, LLC20.00K20.00KNew9.79K
STONEX GROUP INC.23.26K8.50K+57.62%8.67K
CAITLIN JOHN, LLC16.50K00.00%8.08K
COSTON, MCISAAC & PARTNERS17.09K00.00%8.00K

Earnings and financials

GT Biopharma, Inc. (GTBP) trades at $5.59, with a market cap of $7.06M and a trailing P/E of -0.05. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
0000000000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

GT Biopharma (GTBP) Financials: Revenue & Earnings

GTBP$5.59+0.01 +0.27%

$7.06M

Market Cap

-0.05

P/E

22.38

Forward P/E

53

Score

Price History